From boom to bitcoin: A device maker’s unusual pivot

After a government crackdown, bitcoin became Semler Scientific's focus.

June 28, 2025 Check out STAT+

Sponsored By

Mike Reddy for STAT STAT+ | From boom to bitcoin: A device maker's surprising pivot amid a Medicare crackdown Semler Scientific's artery test QuantaFlo helped insurers like UnitedHealth, Aetna profit from Medicare. Now, amid DOJ scrutiny, company shifts to bitcoin. By Casey Ross, Bob Herman, Lizzy Lawrence, and Tara Bannow Molly Ferguson for STAT Balkanization of vaccine policy raises concerns about vaccine uptake, insurance coverage, experts warn Firing of CDC vaccine experts leads U.S. toward a balkanized vaccination policy where guidance may depend on personal preference, not scientific expertise. By Helen Branswell Photo illustration: Christine Kao/STAT; Photos: Adobe STAT+ | Kennedy paves way for flood of wellness companies in white coats It's Big Wellness versus Big Pharma as MAHA firms urge consumers to tune out the medical establishment and take their health into their own hands. By Katie Palmer STAT+ | The CDC's vaccine advisory panel, empowered by RFK Jr., is just getting started A two-day meeting of the committee, newly empowered by HHS Secretary RFK Jr., signaled a major disruption is coming to public health policies. By Jason Mast STAT+ | Despite resumption of NIH grant reviews, research funding gap grew STAT analysis shows that the gap in NIH grant awards compared to past years has grown over the past two months, to $4.7 billion By Megan Molteni and J. Emory Parker STAT+ | Novo Nordisk, seen as lagging in obesity drug race, says it's playing the long game Executives argue coming readouts on next-generation candidates such as CagriSema and amycretin and overall strategy will pay off. By Elaine Chen STAT+ | Opinion: The decades-long journey to Gilead's twice-a-year HIV prevention drug lenacapavir "It looks like an alien molecule": How scientists created Gilead's new HIV prevention drug lencapavir, or Yeztugo. By William Pao Generic cancer drugs used around the world fail quality tests, investigation shows Investigation finds too little or too much active ingredient in about a fifth of all chemotherapy samples; patients in 100 countries at risk By Paul Eccles, Andjela Milivojevic, and and Ramu Sapkota — TBIJ

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Weekend Reads? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser